WallStSmart

Merck & Company Inc (MRK)vsPark Dental Partners, Inc. Common Stock (PARK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 26383% more annual revenue ($66.57B vs $251.37M). MRK leads profitability with a 4.8% profit margin vs -1.4%. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PARK

Avoid

28

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 3.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Intrinsic value data unavailable for PARK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

PARK1 strengths · Avg: 8.0/10
Free Cash FlowQuality
$2.24B8/10

Generating 2.2B in free cash flow

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

PARK4 concerns · Avg: 2.8/10
Market CapQuality
$97.15M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-18.6%2/10

ROE of -18.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : PARK

The strongest argument for PARK centers on Free Cash Flow.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : PARK

The primary concerns for PARK are Market Cap, Operating Margin, Piotroski F-Score. Debt-to-equity of 2.02 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while PARK is a turnaround play — different risk/reward profiles.

PARK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (36/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Park Dental Partners, Inc. Common Stock

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Park Dental Partners, Inc. is a dental resource organization that offers business support services to dentists throughout Minnesota and Wisconsin. The company is headquartered in Roseville, Minnesota.

Visit Website →

Want to dig deeper into these stocks?